IDH2 and central nervous system cancer: In IDH1/2-mutant gliomas, the characteristic alterations included IDH1 R132H, R132G, or R132S substitution and IDH2 R172K or R172G substitution, with frequent co-occurrence of mutations in TP53 (57.6%) and ATRX (43.9%) (Fig. 3G).